Monsanto Articles
Former S-P chief Fred Hassan joins Bausch & Lomb board of directors
13 November 2009
Pfizer to close six global R&D sites as part of post-Wyeth acquisition cost-cutting
10 November 2009
$60M exit package for S-P CEO Hassan?
16 March 2009
Headlines 25 years ago this week....
17 December 2007
Monsanto elects Hugh Grant as CEO
9 June 2003
Stock Commentary - week to Jan 20 - New York
27 January 2003
Pharmacia sets Monsanto share allocation
12 August 2002
Brazilian court considering biotech regs
11 March 2002
Pharmacia 4th-qtr profits take a dip but Celebrex still selling well
11 February 2002
Pharmacia expecting 6%-10% increase in 2002 earnings per share
4 December 2001
Pharmacia's product pipeline; what's in store after Celebrex?
29 November 2001
Pharmacia earnings up 20%, sales rise 5%
25 July 2001
Stock Commentary - Europe
11 April 2001
Hassan becomes Pharmacia chairman as Shapiro resigns
1 February 2001
CuraGen revenues climb 38%
26 January 2001
The US "biotech century" began with a boom in 2000, says Burrill
25 January 2001
Epimmune returned cancer vaccine program
15 November 2000
Monsanto IPO raises $700 million
19 October 2000
IBM investing $100 million in life sciences
18 August 2000
Pharmacia plans for Japanese market
21 July 2000
Pharmacia completes Spanish restructuring
19 July 2000
Myriad gets $24M from Euro pharma firm
30 June 2000
Appointment at Celera
8 June 2000
Myriad and Hitachi sign proteomics deal
18 May 2000
Head of Pharmacia in Japan appointed
18 May 2000
Monsanto IPO to raise $100 million
16 May 2000
Pharmacia's EPS up 27% in 1st quarter
26 April 2000
AHP going ahead with fen-phen settlement
17 April 2000
Stock Commentary Europe
13 April 2000
Stock Commentary New York
6 April 2000
P&U/Monsanto merger cleared by EU
4 April 2000
P&U to make decision on Vestra
3 April 2000
Searle to conduct global Phase III trial of eplerenone
29 March 2000
EC extends deadline on Monsanto/P&U merger
16 March 2000
Pharmacia & Upjohn and Monsanto both post strong results for 1999
11 February 2000
Stock Commentary Europe
10 February 2000
Stock Commentary Europe
3 February 2000
P&U and Monsanto decide on new name
28 January 2000
Six largest US PBMs place Celebrex on national formularies
20 January 2000
Stock Commentary Europe
13 January 2000
Stock Commentary New York
13 January 2000
DuPont shies away from drug alliances
12 January 2000
Stock Commentary Europe
6 January 2000
Stock Commentary New York
6 January 2000
Monsanto pays out $81 million break-up fee
5 January 2000
CAT signs possible $200M deal with Searle
4 January 2000
Mixed reaction to P&U and Monsanto's planned merger
21 December 1999
BI gets approvable letter for Mobic in USA
21 December 1999
Monsanto to spin off pharma operations?
13 December 1999
AHP link-up with P&U if the Warner deal fails?
10 December 1999
Stock Commentary New York
9 December 1999
Novartis to increase investment in Spain
26 November 1999
Stock Commentary Europe
25 November 1999
Appointment at Monsanto
25 November 1999
Stock Commentary Tokyo
18 November 1999
Stock Commentary New York
11 November 1999
Stock Commentary Europe
11 November 1999
Novartis link-up with Monsanto mooted
10 November 1999
American Home Products confirms merger talks with Warner-Lambert
3 November 1999
Merck victorious in COX-2 patent dispute
11 October 1999
Stock Commentary Europe
16 September 1999
EU "no plans to move on life science firms"
15 September 1999
Biogen appointment
9 September 1999
Stock Commentary Tokyo
9 September 1999
Pfizer/Monsanto act on drug name confusion
1 September 1999
Celebrex sales drive Monsanto earnings rise
29 July 1999
Vioxx hot on the tails of Celecoxib
15 July 1999
Stock Commentary New York
15 July 1999
Alternative delivery mkt set for fast growth
12 July 1999
Stock Commentary Tokyo
17 June 1999
3rd Qtr revenues at Myriad leap 163%
16 June 1999
AHP rumored to be takeover target
14 June 1999
Stock Commentary New York
27 May 1999
Stock Commentary Tokyo
29 April 1999
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
